A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With moderate-to- Severe Active Ulcerative Colitis
Latest Information Update: 13 Feb 2026
At a glance
- Drugs SHR 1139 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 10 Feb 2026 Status changed from not yet recruiting to recruiting.
- 26 Nov 2025 New trial record